# reload+after+2024-01-20 09:48:03.148933
address1§945 Concord Street
city§Framingham
state§MA
zip§01701
country§United States
phone§781 778 7720
website§https://www.xeneticbio.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. In addition, the company leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, and PJSC Pharmsynthez. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
fullTimeEmployees§4
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Jeffrey F. Eisenberg Esq.', 'age': 57, 'title': 'CEO, President & Director', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 533945, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. James F. Parslow', 'age': 58, 'title': 'CFO, COO & Corporate Secretary', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 424549, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Curtis A. Lockshin', 'age': 63, 'title': 'Chief Scientific Officer', 'yearBorn': 1960, 'fiscalYear': 2022, 'totalPay': 420930, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
beta§2.628
currency§USD
exchange§NMS
quoteType§EQUITY
shortName§Xenetic Biosciences, Inc.
longName§Xenetic Biosciences, Inc.
firstTradeDateEpochUtc§1563888600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§df396064-cf1f-3f91-a2af-8089a432fbf8
gmtOffSetMilliseconds§-18000000
recommendationKey§none
quickRatio§9.149
grossMargins§1.0
ebitdaMargins§0.0
trailingPegRatio§None
